Osivax is developing universal vaccines using its oligoDOM® self-assembling nanoparticles platform, which triggers strong T-cell responses against conserved viral antigens. This technology aims to provide long-term protection against highly mutating pathogens, including current and future strains of influenza and coronaviruses.
Funding
$35M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NIFounders
Product
Problem
Current vaccines often fail to provide broad, long-lasting protection against rapidly evolving viruses like influenza and coronaviruses, necessitating frequent reformulation and revaccination. Traditional vaccine approaches may not elicit strong T-cell responses, which are crucial for clearing infected cells and providing cross-strain immunity.
Solution
Osivax is developing universal vaccines leveraging its oligoDOM® platform, a self-assembling nanoparticle technology designed to stimulate potent T-cell responses against conserved viral antigens. By targeting these internal, less mutable viral components, the oligoDOM® platform aims to provide broad protection against existing and future strains of highly mutating pathogens. Osivax combines its T-cell technology with antibody-based approaches to develop a new generation of vaccines that empower both arms of the immune system. This strategy seeks to address the limitations of current vaccines and offer more durable immunity against global infectious diseases.
Target Audience
The primary target audience includes individuals seeking broad and long-lasting protection against highly mutating viruses, as well as public health organizations aiming to control the spread of infectious diseases.
Features
- Utilizes the oligoDOM® self-assembling nanoparticle platform to deliver conserved viral antigens.
- Designed to trigger strong T-cell responses against internal viral proteins.
- Aims to provide broad protection against current and future strains of influenza and coronaviruses.
- Can be combined with traditional antibody-based vaccine approaches.